Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 177 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Tumor fluorescence Clear all

Conditions: Colorectal Cancer, Neoplasm of Uncertain Malignant Potential
Interventions: DNA methylation analysis, fluorescence in situ hybridization, gene expression analysis, polymerase chain reaction, protein expression analysis, reverse transcriptase-polymerase chain reaction, diagnostic laboratory biomarker analysis, immunoenzyme technique, immunohistochemistry staining method, biopsy, therapeutic conventional surgery, fludeoxyglucose F 18; Genetic · Other · Procedure + 1 more
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 15 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Squamous Cell Carcinoma of the Oral Cavity, Oropharynx, Larynx, Hypopharynx
Interventions: Not listed
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Invasive Breast Cancer
Interventions: Smart Goggle, Cardio-Green, SPY Elite Imaging system, Quest near-infrared (NIR) Imaging system, PDE Imaging system, Gamma probe, Blue Dyes; Device · Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Lung Cancer in Normal and Malignant Tumors
Interventions: ALA-induced Fluorescence; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Cancer
Interventions: graft versus host disease prophylaxis/therapy, fluorescence in situ hybridization, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, in vitro-treated bone marrow transplantation, management of therapy complications; Biological · Genetic · Other + 1 more
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 8
States / cities: Cleveland, Ohio

Conditions: Malignant Glioma of Brain
Interventions: 5ALA exoscopic fluorescence filter; Diagnostic Test
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Head and Neck Melanoma
Interventions: fluorescent cRGDY-PEG-Cy5.5-C dots; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 2
States / cities: New York, New York

Conditions: Stage I Breast Cancer, Stage II Breast Cancer
Interventions: Indocyanine Green Solution, Technetium Tc-99m Sulfur Colloid, Lymphoscintigraphy, Axillary Lymph Node Biopsy; Drug · Radiation · Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: Female only
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Carcinoma, Basal Cell, Carcinoma, Squamous Cell
Interventions: Polarization Enhanced Reflectance and Fluorescence System; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Non-Melanoma Skin Cancer (NMSC), Benign Skin Growth
Interventions: Ameluz 10% Topical Gel, Protoporphyrin IX; Drug · Device
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: High-Grade Glioma (WHO III-IV)
Interventions: FG001; Drug
Lead sponsor: FluoGuide A/S; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 5
States / cities: Miami, Florida • Lebanon, New Hampshire • Pittsburgh, Pennsylvania + 2 more

Conditions: Head and Neck Cancer
Interventions: Panitumumab IRDye 800, da Vinci Firefly, IMAGE1 + ICG Hopkins telescope and/or VITOM; Drug · Device
Lead sponsor: Eben Rosenthal; Other
Eligibility: 19 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 2
States / cities: Birmingham, Alabama • Stanford, California

Conditions: Rectal Neoplasms
Interventions: Endoscopic injection of 99mTc-sulfur colloid, Endoscopic injection of ICG, Endoscopic injection of Spot, Flexible sigmoidoscopy, Endoscopic NIR imaging and gamma probe, Dissection of sentinel lymph node(s); Other · Procedure
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2016
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Anemia, Metastatic Cancer, Myelodysplastic Syndromes, Precancerous Condition, Prostate Cancer
Interventions: fluorescence in situ hybridization, microarray analysis, molecular diagnostic method, immunohistochemistry staining method, laboratory biomarker analysis, biopsy, immunoscintigraphy; Genetic · Other · Procedure
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 40 Years and older · Male only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Meningioma
Interventions: Gleolan; Drug
Lead sponsor: NX Development Corp; Industry
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 15
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 12 more

Conditions: Malignant Brain Tumors, Glioma
Interventions: SBK2-ICG, Craniotomy (Standard of Care); Drug · Procedure
Lead sponsor: Tiffany Hodges; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Cleveland, Ohio • Dayton, Ohio

Conditions: Breast Cancer, Cancer of the Breast
Interventions: LS301, Cancer Vision Goggles and standard fluorescence imaging systems, Surgery; Drug · Device · Procedure
Lead sponsor: Samuel Achilefu; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Primary Invasive Malignant Neoplasm of Female Breast, Carcinoma Breast, Breast Cancer Female, Carcinoma, Ductal, Breast, Stage II Breast Cancer, Stage I Breast Cancer, Stage III Breast Cancer
Interventions: Investigational Imaging device, AVB-620; Device · Drug
Lead sponsor: Avelas Biosciences, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 13
States / cities: San Diego, California • Washington D.C., District of Columbia • Jacksonville, Florida + 10 more

Conditions: Locally Advanced Colorectal Carcinoma, Recurrent Colorectal Carcinoma, Stage III Colorectal Cancer
Interventions: Aminolevulinic Acid, Biospecimen Collection, Computed Tomography, Fluorescence-Guided Surgery, Magnetic Resonance Imaging, Photodynamic Therapy, Surgical Procedure; Drug · Procedure
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Ovarian Cancer
Interventions: Gleolan; Drug
Lead sponsor: NX Development Corp; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 11
States / cities: Phoenix, Arizona • Jacksonville, Florida • Annapolis, Maryland + 8 more

Conditions: Breast Cancer
Interventions: dextromethorphan hydrobromide, tamoxifen citrate, high performance liquid chromatography, laboratory biomarker analysis, pharmacogenomic studies, pharmacological study, fluorescence imaging; Drug · Other · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 2
States / cities: Scottsdale, Arizona • Rochester, Minnesota

Conditions: Brain Tumors
Interventions: 5-aminolevulinic acid; Drug
Lead sponsor: David W. Roberts; Other
Eligibility: 21 Years and older
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2028
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Prostate Carcinoma
Interventions: Biospecimen Collection; Procedure
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 50 Years to 79 Years · Male only
Enrollment: 810 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Bladder Cancer
Interventions: Hexvix, Standard white light cystoscopy; Drug · Procedure
Lead sponsor: Photocure; Industry
Eligibility: 18 Years and older
Enrollment: 789 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 15
States / cities: Stanford, California • Gainesville, Florida • Miami, Florida + 12 more

Search by objective public record fields.

Fludeoxyglucose F 18 PET Imaging in Determining Protein and Gene Expression Signatures in Patients With Premalignant Polyps or Colon Cancer

Ex Vivo Multimodal Imaging of Upper Aerodigestive Epithelium

Evaluation of an Integrated Imaging System For In Vivo Detection of Fluorescently Labeled Lesions

A Proof of Principle Study of Aminolevulinic Acid (ALA) - Induced Fluorescence Detection in Resectable Non-Small Cell Lung Cancer

Donor Mesenchymal Stem Cell Infusion in Treating Patients With Acute or Chronic Graft-Versus-Host Disease After Undergoing a Donor Stem Cell Transplant

Pilot Study Evaluating the Optimization of the ORBEYE Blue Light Filter During Fluorescence-Guided Resection of Gliomas

Targeted Silica Nanoparticles for Real-Time Image-Guided Intraoperative Mapping of Nodal Metastases

Comparison of Use of Indocyanine Green and 99mTc-labeled Radiotracer for Axillary Lymphatic Mapping in Patients With Breast Cancer

Optical Imaging for Preoperative Delineation of Nonmelanoma Skin Cancers

Assessment of Skin Lesions Using a Tissue Oxygen Imager Based on Protoporphyrin IX (PPIX) Fluorescence. This is an Open-label, Non-randomized, Feasibility Study That Includes a One-time Application of an FDA Approved Medication Followed by Local Imaging for Benign Skin Growth and Lesions Clinically

FG001 Near-Infrared Fluorescence Imaging During Tumor Resection in Newly Diagnosed High-Grade Glioma

Panitumumab IRDye800 Optical Imaging Study

Sentinel Lymph Node Mapping in Rectal Cancer

Proteases in Patients With Prostate Cancer That Has Spread to the Bone

Gleolan for Visualization of Newly Diagnosed or Recurrent Meningioma

Fluorescence-Guided Imaging of Brain Tumors: A Safety Study Using SBK2-ICG

Real-time Intraoperative Breast Cancer Visualization for Margin Assessment

Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery

Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurrent Colorectal Cancer

Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)

Breath Test for Women Receiving Tamoxifen in the Prevention or Treatment of Breast Cancer

ALA-induced PpIX Fluorescence During Brain Tumor Resection

Investigation Into Detection of Prostate Cancer Using Voided Urine (Prostate VPAC)

Study to Improve Detection and Early Recurrence Rate in Bladder Cancer Patients Using Hexvix Fluorescence Cystoscopy